Drug Profile
NLA 102
Alternative Names: Progenitor cell CARs - Nohla Therapeutics; Progenitor cell chimeric antigen receptor therapy - Nohla TherapeuticsLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Nohla Therapeutics
- Class Immunotherapies; Stem cell therapies
- Mechanism of Action Cell replacements; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 10 Jan 2017 Preclinical trials in Cancer in USA (Parenteral)